OncoMatch/Clinical Trials/NCT06663098
Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
Is NCT06663098 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Atezolizumab and Carboplatin for extensive stage small cell lung cancer (es-sclc).
Treatment: Atezolizumab · Carboplatin · Etoposide — The goal of this clinical trial is to learn if a combination of atezolizumab and standard chemotherapy works to treat sensitive Extensive-stage Small Cell Lung Cancer, progressing after first-line of treatment. The main questions it aims to answer are: * Does combination of atezolizumab and standard chemotherapy increase overall survival? * What medical problems do participants have when taking combination of atezolizumab and standard chemotherapy? Participants will: * take atezolizumab and standard chemotherapy every 3 weeks for 4 cycles and than atezolizumab every 3 weeks up to 18 cycles. * visit the clinic once every 3 weeks for checkups and tests * perform Radiological assessments after 6 weeks and then every 12 weeks to determine response to treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV (SCLC)
Extensive-stage Small Cell Lung Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy — first-line
Disease progression at least 60 days after the completion of first-line chemotherapy consisting of at least 4 cycles of platinum-etoposide plus either atezolizumab or durvalumab and have not received any other treatment (except for immunotherapy as maintenance treatment)
Must have received: anti-PD-L1 therapy (atezolizumab, durvalumab) — first-line
first-line chemotherapy consisting of at least 4 cycles of platinum-etoposide plus either atezolizumab or durvalumab
Cannot have received: chemotherapy other than platinum-etoposide
First-line chemotherapy other than platinum-etoposide
Cannot have received: more than 1 line of prior treatment
More than 1 line of prior treatment for ES-SCLC
Lab requirements
Blood counts
ANC ≥1500/mm3; Platelet count ≥ 100 x 10^9/L (≥100,000/μL) without transfusion; Hemoglobin ≥ 90 g/L (≥ 9 g/dL); patients may be transfused to meet this criterion
Kidney function
Creatinine < 1.5x ULN or estimated creatinine clearance ≥ 30 mL/min (Cockcroft-Gault) for patients with creatinine above institutional limits
Liver function
Total bilirubin < 1.5x ULN; ALT or AST < 2.5x ULN (< 5x if due to liver metastases)
Normal baseline laboratory values as specified below: * Absolute neutrophil count (ANC) ≥1500/mm3 * Platelet count ≥ 100 x 109/L (≥100,000/μL) without transfusion * Hemoglobin ≥ 90 g/L (≥ 9 g/dL); patients may be transfused to meet this criterion. * Total bilirubin < 1.5x the institutional upper limit of normal (ULN) * Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5x the institutional ULN (< 5x if liver function test elevations are due to liver metastases) * Creatinine < 1.5x institutional ULN or estimated creatinine clearance using the Cockcroft-Gault formula ≥ 30 mL/minute for patients with creatinine levels above institutional limits
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06663098 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy other than platinum-etoposide, more than 1 line of prior treatment disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages